US Capitol Capsule: Innovation without high drug prices: A difficult conversation
This article was originally published in Scrip
Executive Summary
The US, which spends about $300bn per year on pharmaceuticals, is at a crossroads where it must address the fact that the nation cannot sustain the high prices of some medicines, while also ensuring the drug industry has sufficient return on investment to support innovation in new therapies, said Steve Miller, senior vice president and chief medical officer for pharmacy benefit management (PBM) company Express Scripts.